
PAID CLINICAL TRIAL
- Lasting 1 year
- 12 clinic visits
YOU MAY BE ELIGIBLE TO PARTICIPATE IF YOU MEET THE FOLLOWING CRITERIA:
- Are 18 years of age or older
- Diagnosis of Asthma
The purpose of this study is to investigate the effectiveness and safety of benralizumab 30 milligram subcutaneous as an add-on therapy in uncontrolled eosinophilic asthma patients treated with a medium dose of ICS-L AB A compared to conventional escalation to high dose ICS-L ABA treatment.
Lynn Institute is a leader in introducing new medications to the market through our clinical trials program. Visit our Participation Information page for Frequently Asked Questions, to see current clinical trials listed, and to find out where each trial is being conducted.
Find out More About Our Participation Program
Participation Information